Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Investment analysts at Chardan Capital decreased their FY2024 earnings estimates for Lexeo Therapeutics in a research note issued to investors on Wednesday, November 13th. Chardan Capital analyst G. Livshits now forecasts that the company will earn ($3.03) per share for the year, down from their previous forecast of ($2.93). Chardan Capital has a "Buy" rating and a $25.00 price objective on the stock. The consensus estimate for Lexeo Therapeutics' current full-year earnings is ($3.05) per share. Chardan Capital also issued estimates for Lexeo Therapeutics' FY2025 earnings at ($2.30) EPS.
A number of other brokerages have also recently weighed in on LXEO. Leerink Partners reduced their price objective on Lexeo Therapeutics from $20.00 to $19.00 and set an "outperform" rating for the company in a research note on Wednesday, November 13th. Royal Bank of Canada reiterated an "outperform" rating and set a $24.00 price target on shares of Lexeo Therapeutics in a research note on Tuesday, August 13th. Finally, HC Wainwright lifted their price objective on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the company a "buy" rating in a research note on Thursday. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $22.71.
Check Out Our Latest Analysis on Lexeo Therapeutics
Lexeo Therapeutics Stock Performance
Shares of Lexeo Therapeutics stock traded down $0.65 on Monday, hitting $6.00. The stock had a trading volume of 503,828 shares, compared to its average volume of 251,480. The company's 50 day moving average price is $9.01 and its 200 day moving average price is $12.23. The stock has a market cap of $198.40 million and a price-to-earnings ratio of -1.93. The company has a current ratio of 5.95, a quick ratio of 9.38 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics has a 52-week low of $5.81 and a 52-week high of $22.33.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in LXEO. BNP Paribas Financial Markets increased its holdings in Lexeo Therapeutics by 184.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company's stock valued at $50,000 after acquiring an additional 3,591 shares in the last quarter. Values First Advisors Inc. purchased a new position in shares of Lexeo Therapeutics during the 3rd quarter worth approximately $67,000. American International Group Inc. acquired a new position in shares of Lexeo Therapeutics during the 1st quarter worth approximately $79,000. MetLife Investment Management LLC lifted its stake in Lexeo Therapeutics by 121.5% in the 3rd quarter. MetLife Investment Management LLC now owns 14,223 shares of the company's stock valued at $129,000 after buying an additional 7,803 shares in the last quarter. Finally, Rhumbline Advisers grew its holdings in Lexeo Therapeutics by 37.3% during the 2nd quarter. Rhumbline Advisers now owns 13,357 shares of the company's stock valued at $214,000 after buying an additional 3,627 shares during the last quarter. Hedge funds and other institutional investors own 60.67% of the company's stock.
Insider Activity
In related news, CEO Richard Nolan Townsend sold 5,000 shares of the company's stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $10.65, for a total value of $53,250.00. Following the sale, the chief executive officer now owns 120,695 shares in the company, valued at $1,285,401.75. This represents a 3.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold a total of 12,500 shares of company stock valued at $113,300 over the last quarter. Corporate insiders own 4.50% of the company's stock.
Lexeo Therapeutics Company Profile
(
Get Free Report)
Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.
Further Reading
Before you consider Lexeo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexeo Therapeutics wasn't on the list.
While Lexeo Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
